SCHEMBL12165352

SCHEMBL12165352

CC(C)C1(O)C(N)=Nc2cc(Cl)ccc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS3 P29474 1/20 0.33
▸ NOS1 P29475 1/20 0.33
▸ NOS2 P35228 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ ALOX15 P16050 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ HPGD P15428 1/20 0.32
▸ ALOX12 P18054 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HCAR2 Q8TDS4 1/20 0.31
▸ HTR3E A5X5Y0 1/20 0.31
▸ HTR3B O95264 1/20 0.31
▸ HTR3A P46098 1/20 0.31
▸ HTR3D Q70Z44 1/20 0.31
▸ HTR3C Q8WXA8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12165373 0.87 NOS3 (0.36) NOS3NOS1NOS2LMNATP53
SCHEMBL12165372 0.87 NOS3 (0.36) NOS3NOS1NOS2LMNATP53
SCHEMBL12164956 0.87 NOS3 (0.36) NOS3NOS1NOS2LMNATP53
SCHEMBL12164936 0.75 MAP3K14 (0.40) NOS3NOS1NOS2TP53SMN1; SMN2
SCHEMBL12165353 0.72 EHMT2 (0.34) NOS3NOS1NOS2LMNATP53
SCHEMBL16572434 0.70 NOS3 (0.35) NOS3NOS1NOS2ALDH1A1ALOX15
SCHEMBL12165042 0.70 IDO1 (0.33) NOS3NOS1NOS2LMNAHTT
SCHEMBL12164927 0.69 PDK2 (0.33) NOS3NOS1NOS2PDK2
SCHEMBL12165348 0.69 CYP1A2 (0.33) LMNAALDH1A1CYP3A4HTR3APDK2
SCHEMBL12165118 0.68 NOS3 (0.36) NOS3NOS1NOS2ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980926-B2 2-aminoindole compounds and methods for the treatment of malaria GENZYME CORPORATION (US) 2015-03-17 — — US disclosed
US-8980926-B2 2-aminoindole compounds and methods for the treatment of malaria GENZYME CORPORATION (US) 2015-03-17 — — US disclosed
US-20120232063-A1 2-Aminoindole Compounds And Methods For The Treatment Of Malaria MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2012-09-13 — — US disclosed
US-20120232063-A1 2-Aminoindole Compounds And Methods For The Treatment Of Malaria MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2012-09-13 — — US disclosed
WO-2011053697-A1 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA GENZYME CORPORATION (US) 2011-05-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232063-A1 2-Aminoindole Compounds And Methods For The Treatment Of Malaria PNMT, AADAT, INMT NOS3 1338/4885NOS1 2105/4885NOS2 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback